1309365-78-3

Basic information

• Product Name: ethyl 2-(2-aminoquinolin-6-yl)benzoate
• Synonyms: ethyl 2-(2-aminoquinolin-6-yl)benzoate
• CAS NO: 1309365-78-3
• Molecular Weight: 292.337
• Mol File: 1309365-78-3.mol

Chemical Properties

• CAS DataBase Reference: ethyl 2-(2-aminoquinolin-6-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(2-aminoquinolin-6-yl)benzoate(1309365-78-3)
• EPA Substance Registry System: ethyl 2-(2-aminoquinolin-6-yl)benzoate(1309365-78-3)

Safety Data

• Hazardous Substances Data: 1309365-78-3(Hazardous Substances Data)

Upstream product

• 269409-99-6 ethyl 2-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzoate 
• 791626-58-9 2-amino-6-bromoquinoline 

Downstream Products

• 1309365-61-4 (2-(2-aminoquinolin-6-yl)phenyl)(4-fluoropiperidin-1-yl)methanone 
• 1309365-68-1 2-(2-aminoquinolin-6-yl)benzoic acid 

Relevant articles and documents

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer?s disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer?s Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I